Abstract

INTRODUCTION

Myeloproliferative neoplasm (MPN) is a clonal condition that can progress to hemostasis and thrombosis anomalies and acute leukemia. Polycythemia vera (PV), essential thrombocytosis (ET) and idiopathic myelofibrosis (IMF) are bcr-abl negative MPN. According to WHO (World Health Organization), presence of the JAK2V617F mutation is one of the diagnosis criteria in the diagnosis of PV, ET and IMF. In this study, it was aimed to investigate the relationship between JAK2V617F mutation and platelet function in a patient with 60 MPN.

METHODS

The study was conducted in Pamukkale University hematology polyclinic patients and in patients who were diagnosed with MPN according to WHO revised criteria. The study included 60 patients, 30 of which were PV, 28 were ET and 2 were IMF. Patients were tested for platelet aggregation by ADP, ristocetin, epinephrine and collagen. Patients’ platelet aggregation tests were made for ADP, ristocetin, epinephrine and collagen, using an aggregometer device.

RESULTS

Among the 60 patients participating in the study, 30 had PV, 28 had ET and 2 had IMF. 28 of the patients were women (46.6%) and 32 were men (53.3%). The presence of JAK2 mutation was detected in 39 patients (65%). The frequency of the JAK2 mutation was detected to be 83.3% for PV, 42.9% for ET, and 100% for IMF. Platelet function disorder was found in 80% of the patients. This ratio was in the patients 76.9% of with positive JAK2 mutation, and 85.7% of patients with negative JAK2 mutation. No statistically significant relationship was found in terms of epinephrine, ristocetin, collagen and ADP values between patients with positive JAK2V617F mutation and patients with negative JAK2V617F mutation.

DISCUSSION AND CONCLUSION

In our study, no correlation was found between JAK2 mutation and platelet function. In conclusion, the platelet dysfunction seen in MPNs is independent of the JAK2 mutation.